USD 11.28
(6.07%)
Year | Operating Expenses | Operating Expenses Growth |
---|---|---|
2023 | 2.41 Billion USD | 11.68% |
2022 | 2.17 Billion USD | 3.03% |
2021 | 2.11 Billion USD | 7.16% |
2020 | 1.97 Billion USD | 18.46% |
2019 | 1.66 Billion USD | -30.07% |
2018 | 2.37 Billion USD | -9.92% |
2017 | 2.64 Billion USD | 0.0% |
Year | Operating Expenses | Operating Expenses Growth |
---|---|---|
2024 Q3 | 533 Million USD | -3.62% |
2024 Q2 | 553 Million USD | 1.84% |
2024 Q1 | 543 Million USD | -9.95% |
2023 Q1 | 564 Million USD | -7.84% |
2023 Q3 | 675 Million USD | 16.58% |
2023 Q2 | 579 Million USD | 2.66% |
2023 Q4 | 603 Million USD | -10.67% |
2023 FY | 2.42 Billion USD | 11.68% |
2022 Q1 | 467 Million USD | -30.3% |
2022 FY | 2.17 Billion USD | 3.03% |
2022 Q4 | 612 Million USD | 7.94% |
2022 Q3 | 567 Million USD | 7.18% |
2022 Q2 | 529 Million USD | 13.28% |
2021 Q2 | 492 Million USD | 9.58% |
2021 FY | 2.11 Billion USD | 7.16% |
2021 Q1 | 449 Million USD | -50.0% |
2021 Q4 | 670 Million USD | 34.27% |
2021 Q3 | 499 Million USD | 1.42% |
2020 Q4 | 898 Million USD | 139.47% |
2020 Q3 | 375 Million USD | 11.94% |
2020 Q2 | 335 Million USD | -7.46% |
2020 Q1 | 362 Million USD | 0.0% |
2020 FY | 1.97 Billion USD | 18.46% |
2019 FY | 1.66 Billion USD | -30.07% |
2018 FY | 2.37 Billion USD | -9.92% |
2017 FY | 2.64 Billion USD | 0.0% |
Name | Operating Expenses | Operating Expenses Difference |
---|---|---|
AbbVie Inc. | 24.83 Billion USD | 90.26% |
Bristol-Myers Squibb Company | 34.31 Billion USD | 92.95% |
Bristol-Myers Squibb Company Ce | 34.31 Billion USD | 92.95% |
Johnson & Johnson | 58.6 Billion USD | 95.872% |
Eli Lilly and Company | 16.71 Billion USD | 85.529% |
Merck & Co., Inc. | 43.98 Billion USD | 94.501% |
Novartis AG | 24.87 Billion USD | 90.274% |
Pfizer Inc. | 25.45 Billion USD | 90.495% |